Does gender-affirming hormone therapy alter insulin resistance in transgender persons?

Abosi-Appeadu, Kessewa; Maertelaere, Anne-Sophie De; Shadid, Samyah; Defreyne, Justine; T’Sjoen, Guy

doi:10.1530/endoabs.56.p366

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are consistent with previous research indicating that transgender men undergoing gender-affirming hormone therapy have a higher prevalence of dyslipidemia 18 and significant changes in LDL-C, TG, and HDL-C after two years of hormone therapy. 23 Healthcare providers should be vigilant in assessing lipid levels and managing cardiovascular risk factors in transgender individuals, particularly transgender men, and provide culturally competent care and education to address their unique needs and promote adherence to lipid-lowering therapies.…”

Section: Hyperlipidemiamentioning

confidence: 99%

Cardiovascular Risks Among the Transgender Population in Rural United States: Spotlight on the Appalachian Region

Ezeh,

Perdoncin,

Ogbu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Gender diverse populations have disproportionately worse cardiovascular (CV) outcomes. However, the data on the prevalence of cardiovascular risk factors among the transgender population in rural Appalachia remains limited. The purpose of this study was to determine the prevalence of CV risk factors among the transgender population in rural Appalachia. Methods This retrospective case-control study from an Appalachian university teaching hospital clinic matched transgender individuals with controls from the same clinic. Logistic regression model was performed to determine the prevalence of CV risk factors among the transgender population in comparison to their cisgender counterparts. Results The total number of transgender and cisgender individuals identified were 89 and 69, respectively. After adjusting for age and family history of atherosclerotic CV disease, transgender status remained independently associated with tobacco use (adjusted odds ratio [aOR] 6.64 [2.59-17.01]) and prediabetes/diabetes mellitus (aOR 3.98 [1.05-15.15]). Among the transgender population, there were increased odds of obesity (aOR 13.39 [3.30-54.30] and hyperlipidemia (aOR 3.46 [1.03-11.59]) in the transgender male group compared to the transgender female group. In another subgroup analysis, transgender individuals who underwent surgical and/or hormonal treatment had significantly higher odds of tobacco use (aOR 6.67 [2.80-15.98]), statin need (aOR 3.97 [1.14-13.81], and alcohol use (aOR 11.31 [1.34-95.53]). Increased statin use tends to be associated with normal LDL levels. Conclusions In rural Appalachia, transgender status is associated with disproportionately higher odds of tobacco use, elevated blood glucose and other CV risk factors.

show abstract

Section: Hyperlipidemiamentioning

confidence: 99%

Cardiovascular Risks Among the Transgender Population in Rural United States: Spotlight on the Appalachian Region

Ezeh,

Perdoncin,

Ogbu

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study

2019

View full text Add to dashboard Cite

Background: Testosterone implants have been used for over eighty years to treat symptoms of hormone deficiency in pre and postmenopausal women. Evidence supports that androgens are breast protective. However, there is a lack of data on the long-term effect of testosterone therapy on the incidence of invasive breast cancer (IBC). This study was specifically designed to investigate the incidence of IBC in pre and postmenopausal women (presenting with symptoms of androgen deficiency) treated with subcutaneous testosterone implants or testosterone implants combined with anastrozole. Methods: The 10-year prospective cohort study was approved in March 2008 at which time recruitment was initiated. Recruitment was closed March 2013. Pre and postmenopausal women receiving at least two pellet insertions were eligible for analysis (N = 1267). Breast cancer incidence rates were reported as an unadjusted, un-weighted value of newly diagnosed cases divided by the sum of 'person-time of observation' for the at-risk population. Incidence rates on testosterone therapy were compared to age-specific Surveillance Epidemiology and End Results (SEER) incidence rates and historical controls. Bootstrap sampling distributions were constructed to verify comparisons and tests of significance that existed between our results and SEER data. Results: As of March 2018, a total of 11 (versus 18 expected) cases of IBC were diagnosed in patients within 240-days following their last testosterone insertion equating to an incidence rate of 165/100000 p-y, which is significantly less than the age-matched SEER expected incidence rate of 271/100000 p-y (p < 0.001) and historical controls. Conclusion: Long term therapy with subcutaneous testosterone, or testosterone combined with anastrozole, did not increase the incidence of IBC. Testosterone should be further investigated for hormone therapy and breast cancer prevention.

show abstract

Does gender-affirming hormone therapy alter insulin resistance in transgender persons?

Cited by 2 publications

References 0 publications

Cardiovascular Risks Among the Transgender Population in Rural United States: Spotlight on the Appalachian Region

Cardiovascular Risks Among the Transgender Population in Rural United States: Spotlight on the Appalachian Region

Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study

Contact Info

Product

Resources

About